OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics
Jacob P. Thyssen, Diamant Thaçi, Thomas Bieber, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1871-1880
Open Access | Times Cited: 9
Jacob P. Thyssen, Diamant Thaçi, Thomas Bieber, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1871-1880
Open Access | Times Cited: 9
Showing 9 citing articles:
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 15
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 15
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
Teppei Hagino, Mai Yoshida, Risa Hamada, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 14
Teppei Hagino, Mai Yoshida, Risa Hamada, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 14
Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 4, pp. 261-269
Closed Access | Times Cited: 6
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 4, pp. 261-269
Closed Access | Times Cited: 6
Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2024)
Closed Access | Times Cited: 4
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2024)
Closed Access | Times Cited: 4
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
Niccolò Gori, Pietro Quaglino, Andrea Chiricozzi, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Niccolò Gori, Pietro Quaglino, Andrea Chiricozzi, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies
Peter Schmid‐Grendelmeier, Melinda Gooderham, Karin Hartmann, et al.
Allergy (2023) Vol. 79, Iss. 1, pp. 174-183
Open Access | Times Cited: 7
Peter Schmid‐Grendelmeier, Melinda Gooderham, Karin Hartmann, et al.
Allergy (2023) Vol. 79, Iss. 1, pp. 174-183
Open Access | Times Cited: 7
Predictive Factors for Primary and Secondary Nonresponders to Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2024)
Closed Access | Times Cited: 1
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2024)
Closed Access | Times Cited: 1
Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review
Dan-Jie Zhao, Xia Li, Hai-Xia Lin, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0306463-e0306463
Open Access
Dan-Jie Zhao, Xia Li, Hai-Xia Lin, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0306463-e0306463
Open Access
